Background: This study aimed to evaluate for the first time whether certain genetic and clinical factors could serve as minimally invasive predictors of survival and toxicity to platinum-based chemotherapy in advanced lung adenocarcinoma. Methods: The study included 121 advanced lung adenocarcinoma patients treated with platinum-based dublets until progression or unacceptable toxicity. Response was evaluated using standard radiological methods and toxicity graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Genotyping was performed using PCR-RFLP. Statistical significance was set at P
CITATION STYLE
Spasic, J., Cavic, M., Stanic, N., Zaric, B., Kovacevic, T., Radosavljevic, D., & Nagorni-Obradovic, L. (2022). Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dose-Response, 20(2). https://doi.org/10.1177/15593258221111666
Mendeley helps you to discover research relevant for your work.